Detalhe da pesquisa
1.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38662991